- Fee assured
- Verified this account
I am a Consultant Haematologist at St Bartholomew’s Hospital, experienced in the diagnosis and treatment of blood disorders, with specific expertise in the treatment of myeloma and leukaemia.
After qualifying, I undertook specialist training in haematology at University College London Hospital and carried out a PhD in Molecular Haematology at Cambridge University, using genomic technologies to better understand the mechanisms of leukaemia development.
I am a member of the British Society for Haematology (BSH), the UK Myeloma Forum and the UK Myeloma Research Alliance. I am currently the chair of the BSH guidelines group for the initial treatment of myeloma, and am the author of numerous peer-reviewed articles and book chapters.
Areas of interest
Haematological malignancy; myeloma; leukaemia; myelodysplasia; myeloproliferative neoplasms; general haematology (including investigation and management of anaemia, high and low white cell counts, neutropenia, high and low platelet counts, iron deficiency, paraproteins)
Current NHS consultant posts held
St Bartholomew's Hospital
Novel treatments and clinical trials for myeloma
Academic Clinical Fellowship for Haematology specialist training
Cancer Research UK Clinical Research Fellowship for PhD at Cambridge University
American Society of Hematology Abstract Achievement Award
Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival. Chin M, Sive JI, Allen C, Roddie C, Chavda SJ, Smith D, Blombery P, Jones K, Ryland GL, Popat R, Rismani A, D'Sa S, Rabin N, Gale RE, Yong KL. Blood Cancer J. 2017 Sep 15;7(9):
Genome-scale definition of the transcriptional programme associated with compromised PU.1 activity in acute myeloid leukaemia. Sive JI, Basilico S, Hannah R, Kinston SJ, Calero-Nieto FJ, Göttgens B. Leukemia. 2016 Jan;30(1):14-23.
Global hypomethylation in myeloma is associated with poor prognosis. Sive JI, Feber A, Smith D, Quinn J, Beck S, Yong K. Br J Haematol. 2016 Feb;172(3):473-5.
Transcriptional network control of normal and leukaemic haematopoiesis. Sive JI, Göttgens B.
Exp Cell Res. 2014 Dec 10;329(2):255-64.
Bivalent promoter marks and a latent enhancer may prime the leukaemia oncogene LMO1 for ectopic expression in T-cell leukaemia. Oram SH, Thoms J, Sive JI, Calero-Nieto FJ, Kinston SJ, Schütte J, Knezevic K, Lock RB, Pimanda JE, Göttgens B. Leukemia. 2013 Jun;27(6):1348-57.
Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adults. Sive JI, Thomson KJ, Morris EC, Ward KN, Peggs KS.
Clin Infect Dis. 2012 Nov 15;55(10):1362-70.
Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experience. Sive J, Ardeshna KM, Cheesman S, le Grange F, Morris S, Nicholas C, Peggs K, Statham P, Goldstone AH. Leuk Lymphoma. 2012 Dec;53(12):2397-404.
Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Sive JI, Buck G, Fielding A, Lazarus HM, Litzow MR, Luger S, Marks DI, McMillan A, Moorman AV, Richards SM, Rowe JM, Tallman MS, Goldstone AH. Br J Haematol. 2012 May;157(4):463-71.
- MBChB University of Manchester 2002
- PhD University of Cambridge 2016
- MRCP Royal College of Physicians 2005
- FRCPath Royal College of Pathologists 2013
Reference number 6054442
Professional bodies (positions held - last 3 yrs)
- Consultant Haematologist St Bartholomew's Hospital 2016
Affiliations / memberships
British Society for Haematology
UK Myeloma Forum
UK Myeloma Research Alliance
- University College Hospital235 Euston...
- 08:00 - 13:00
- 020 3447 1719
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.